tiprankstipranks
Trending News
More News >
Omid Holdings Inc (OMID)
:OMID
US Market
Advertisement

OMID Holdings (OMID) AI Stock Analysis

Compare
8 Followers

Top Page

OMID

OMID Holdings

(OTC:OMID)

Rating:42Neutral
Price Target:
OMID Holdings is facing significant financial and operational challenges, reflected in poor financial performance and negative valuation metrics. Technical analysis indicates bearish momentum, and the absence of strong earnings call insights adds to the uncertainty. The overall score reflects these challenges, highlighting the need for improved operational efficiency and revenue growth.

OMID Holdings (OMID) vs. SPDR S&P 500 ETF (SPY)

OMID Holdings Business Overview & Revenue Model

Company DescriptionOMID Holdings, Inc., a health and wellness company, engages in the manufacture and sale of CBD-based products. The company is based in Phillipsburg, New Jersey.
How the Company Makes MoneyOMID Holdings generates revenue primarily through the sale of its hemp and CBD-based products. These products are distributed through various retail and online channels, allowing the company to reach a broad consumer base. Key revenue streams include direct sales to consumers via the company's e-commerce platform and wholesale distribution partnerships with retailers. OMID may also engage in strategic collaborations with other companies in the industry to broaden its market reach and enhance product offerings. The company's earnings are influenced by factors such as consumer demand for wellness products, regulatory developments in the hemp and CBD industry, and the effectiveness of its marketing strategies.

OMID Holdings Financial Statement Overview

Summary
OMID Holdings faces financial challenges with declining revenues and profitability issues. Despite some improvement in gross profit margin and positive equity growth, high leverage and weak cash flow generation present significant risks.
Income Statement
35
Negative
OMID Holdings has faced significant revenue decline from 2021 to 2023, with a notable drop in profitability metrics. The gross profit margin has improved from negative to positive in 2023, indicating some recovery in cost management. However, the net profit margin remains weak despite a return to profitability in 2023, and EBIT continues to be negative, suggesting operational challenges.
Balance Sheet
55
Neutral
The balance sheet shows a reasonable equity ratio, though it has declined over recent years, indicating a reduction in financial stability. The debt-to-equity ratio is relatively stable but slightly elevated, which could pose risks if profitability does not improve. The positive growth in stockholders' equity from 2022 to 2023 is a positive sign.
Cash Flow
30
Negative
OMID Holdings has struggled with negative free cash flow in recent years, significantly impacting its liquidity position. The operating cash flow remains negative, indicating ongoing challenges in generating cash from operations. There has been some reduction in capital expenditures, but overall cash flow health is concerning.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue247.59K522.24K1.55M2.15M1.33M
Gross Profit-275.31K60.21K-87.82K853.70K637.61K
EBITDA-476.25K57.40K-444.86K559.95K437.58K
Net Income-850.59K34.64K-330.53K484.05K425.76K
Balance Sheet
Total Assets828.01K818.02K912.49K1.68M577.65K
Cash, Cash Equivalents and Short-Term Investments646.08K137.82K469.94K931.38K262.66K
Total Debt333.97K342.86K339.57K351.18K86.10K
Total Liabilities378.78K402.44K592.39K1.04M261.82K
Stockholders Equity449.23K415.58K320.10K639.40K315.83K
Cash Flow
Free Cash Flow-367.10K-427.70K-478.75K307.50K58.94K
Operating Cash Flow-367.10K-408.04K-420.87K341.07K140.18K
Investing Cash Flow-64.34K-19.66K-57.88K-33.57K-81.24K
Financing Cash Flow563.04K56.73K68.42K227.94K200.60K

OMID Holdings Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.02
Price Trends
50DMA
0.02
Positive
100DMA
0.02
Positive
200DMA
0.02
Negative
Market Momentum
MACD
<0.01
Positive
RSI
50.28
Neutral
STOCH
140.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OMID, the sentiment is Neutral. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.28 is Neutral, neither overbought nor oversold. The STOCH value of 140.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OMID.

OMID Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
$13.88M3.29%-26.17%
52
Neutral
$2.00M2.66%-27.81%
51
Neutral
$7.93B-0.32-43.43%2.21%22.30%-1.88%
46
Neutral
$19.61M-52.69%
44
Neutral
$6.51M-33.13%-7.80%90.17%
42
Neutral
$1.45M-167.84%109.73%-134.29%
$2.44M-1460.27%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
OMID
OMID Holdings
0.02
0.00
0.00%
AYTU
Aytu BioScience
2.33
-0.15
-6.05%
YCBD
cbdMD
0.72
-3.68
-83.64%
COSM
Cosmos Holdings
0.67
-0.43
-39.09%
UPC
Universe Pharmaceuticals
3.78
-1,850.22
-99.80%
AKAN
Akanda Corp
3.35
-3.71
-52.55%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 03, 2025